This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In India, pharmaceuticalcompanies responded to global environmental concerns and government mandates by adopting greener manufacturing techniques. To move from generics to novel drug development, Indian companies must invest heavily in R&D for innovative therapies like biosimilars, cell and gene therapies, and specialty drugs.
Alvotech and Advanz Pharmaceutical have extended their partnership, regarding the supply and commercialisation of five proposed biosimilars in Europe. The company responsible for development and commercial supply of the biologic medicines is Alvotech, a global biotech company specialising in biosimilar treatments.
The first stage of construction has officially begun on Lek Pharmaceuticals’ new biologics and biosimilars production centre in Lendava, north eastern Slovenia. Sandoz announced plans for the facility in March 2023. Sandoz is the parent company of Lek Pharmaceuticals , the oldest pharmaceuticalcompany in Slovenia.
“approval [of Pyzchiva ® (biosimilar ustekinumab)] of is a crucial step towards offering European patients an additional safe and effective treatment option” Pharmaceuticalcompany Sandoz has announced that the European Commission (EC) has granted marketing authorisation for Pyzchiva ® (biosimilar ustekinumab ).
Hetero Labs Limited-Walk-In Interviews for Production/ EHS/ Engineering- API On 26th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Hetero also offers custom pharmaceutical services to its partners around the world.
Hetero Limited-Campus Interview for B.Sc / M.Sc -Chemistry/ B.Com/ B.Pharm/ ITI Fitter/ Diploma Mechanical On 9th Jan’ 2023. Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Date of Interview: 9th Jan’ 2023. Job Description.
Hetero Labs Limited-Walk-In Interviews for Freshers in Production/ QA/ QC/ Maintenance On 5th Mar’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”.
Hetero Labs Limited-Placement Drive for Freshers in Production/ QA QC/ Engineering On 16th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”.
Chemistry/ B.Com Freshers On 14th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.
Walk-In Interviews for fresher -Apprentice Trainee On 8th Feb’ 2023 Job Description Dr. Reddy’s Laboratories Ltd. is an integrated global pharmaceuticalcompany, committed to providing affordable and innovative medicines for healthier lives. Walk-In Interviews for fresher -Apprentice Trainee On 8th Feb’ 2023
Hetero Labs Limited-Walk-In Interviews for Freshers & Experienced in Production/Packing/ QA/ Stores On 4th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”.
Hetero Labs Limited-Walk-In Interviews for Freshers & Experienced in QC -Instrumentation On 4th Mar’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Dear, Greetings from Hetero…!!
Walk-In Drive for Multiple Positions On 8th Jan’ 2023. is an integrated global pharmaceuticalcompany, committed to providing affordable and innovative medicines for healthier lives. Through its three business-Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Job Description.
Hetero Labs Limited-Walk-In Interviews for Freshers in Production/ QA/ QC/ Maintenance On 21st Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”.
Hetero Labs Limited-Walk-In Interviews for Freshers in Quality Control/ Quality Assurance/ Production On 5th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Chemist Qualification: B.Sc
Hetero Labs Limited-Walk-In Interviews for AR&D/ FR&D/ Analytical DQA On 28th Jan’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”.
Hetero Labs Limited-Walk-In Interviews for Freshers in QC/ QA/ R&D/ Production/ HR/ Maintenance On 29th Jan’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”.
Hetero Labs Limited-Walk-In Interviews for Quality Control/ Quality Assurance/ Engineering/ Safety -EHS On 29th Jan’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”.
in Regulatory Affairs On 17th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.
Hetero Labs Limited-Walk-In Interviews for Freshers in QA/ QC/ Production On 3rd Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Hetero also offers custom pharmaceutical services to its partners around the world.
On 8th Jan’ 2023. is an integrated global pharmaceuticalcompany, committed to providing affordable and innovative medicines for healthier lives. Through its three business-Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Company Name: Dr. Reddy’s Laboratories.
Biocon has signed a partnership agreement with Juno Pharmaceuticals, a specialty pharmaceuticalcompany in Canada, for the commercialisation of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.
a specialty pharmaceuticalcompany in Brazil, for the commercialisation of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes. The post Biocon signs licensing and supply pact with Biomm S.A
Amgen drug development highlights – November 2023 In November 2023, Phase II trial results for immunotherapy tarlatamab demonstrated an ability to provide sustained anti-tumour activity in 40 percent of the small cell lung cancer trial patients.
Congress and the White House to curtail prescription drug prices, many experts continue to point to biosimilars and their promising potential to usher in competition, increase access, and drive down costs for patients—and the U.S. And already in the first quarter of 2022, the FDA approved a third filgrastim biosimilar, Releuko.
Hetero Labs Limited-Walk-In Interviews for Production On 26th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics.
Hetero Labs Limited-Walk-In Drive for Any Graduate in Production- API On 19th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Hetero also offers custom pharmaceutical services to its partners around the world.
Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Hetero’s business includes APIs, generic, biosimilars, custom pharmaceutical services, and branded generics. Time: 10:00 AM Onwards. hetero.com.
Hetero Labs Limited-Walk-In Interviews for Freshers & Experienced On 6th & 7th Jan’ 2023. Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Hetero also offers custom pharmaceutical services to its partners around the world.
Hetero Labs Limited-Campus Drive for B.Sc /B.Pharm/ M.Sc/ BCCA/ ITI Fitter/ Diploma/ B.Com/ Diploma Freshers On 6th Feb’ 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”.
Hetero Labs Limited-Walk-In Interviews for Freshers & experienced in Production/ Packing/ QC/ QA/ Stores On 4th March 2023 Job Description Hetero Labs Limited is one of India’s generic pharmaceuticalcompanies and the “world’s largest producer of anti- retroviral drugs”. Dear, Greetings from Hetero…!!
For pharmaceuticalcompanies, this creates both opportunity and urgency: drugs that demonstrate clear clinical benefit could gain swift recognition, while those without competitive differentiation may be deprioritised in treatment algorithms.
Untamed inflation is a top concern for the pharmaceutical industry globally in 2023. This could evolve into pharmaceuticalcompanies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The entire pharma industry will be affected by the fallout.
On May 26, 2023, the European Commission granted the marketing authorization to Samsung Bioepis for EPYSQLI, a biosimilar referencing SOLIRIS (eculizumab) developed by Alexion for the treatment of the paroxysmal nocturnal hemoglobinuria (PNH) that had global sales of approximately $5 trillion last year.
billion in 2023 to $17.9 However, balancing affordability and accessibility with clinical efficacy remains a challenge that pharmaceuticalcompanies must continue to navigate.” Primarily, the loss of patent protection for several drugs, such as Evenity, will lead to the launch of more generics and biosimilars.
Legislative hurdles aside, in the same way as any other pharmaceuticalcompanies, psychedelics companies will need to obtain regulatory approvals in the countries where they will carry out clinical trials or market products. Sian Banks is a Solicitor within Pinsent Masons’ international intellectual property group.
Untamed inflation is a top concern for the pharmaceutical industry globally in 2023. This could evolve into pharmaceuticalcompanies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The entire pharma industry will be affected by the fallout.
2) limiting the scope and number of patents asserted in litigation against proposed biosimilar entrants. 4) prohibiting ‘product hopping’ and interference with generic and biosimilar substitutions. 5) monitoring access to biosimilars. 3) policing anticompetitive settlements between competing drug manufacturers.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content